Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02175290
Other study ID # MMC140006CTIL
Secondary ID
Status Recruiting
Phase N/A
First received June 22, 2014
Last updated March 15, 2017
Start date June 2014
Est. completion date June 2018

Study information

Verified date April 2016
Source Meir Medical Center
Contact Carlos R Gordon, MD;DSc
Phone 972-9-7471581
Email cgordon@post.tau.ac.il
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Machado-Joseph disease (MJD) or spinocerebellar ataxia type 3 (SCA-3) is the most common dominant ataxia. The genetic cause of this late-onset degenerative disorder is the expansion of a (CAG)n tract located in the exonic region of the ATXN3 gene. In 1994 the first case of MJD among the Yemenite Jewish subpopulation living in Israel was published. The puropse of this study is to describe the clinical phenotype and genotype of the Yemenite Jewish subpopulation with MJD living in Israel


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date June 2018
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Spinocerebellar Ataxia 3 Yemenite Jews patients

Exclusion Criteria:

- All others

Study Design


Locations

Country Name City State
Israel Department of Neurology, Meir Medical Center Kfar-saba

Sponsors (1)

Lead Sponsor Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary clinical phenotype of SCA3 Yemenite Jews patients 3 years
See also
  Status Clinical Trial Phase
Completed NCT04426149 - Clinical Effects of Oral Trehalose In Patients With Spinocerebellar Ataxia 3 N/A
Completed NCT03120013 - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia N/A
Active, not recruiting NCT03408080 - Open Pilot Trial of BHV-4157 Phase 3
Completed NCT04153110 - Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia N/A
Active, not recruiting NCT03487367 - Clinical Trial Readiness for SCA1 and SCA3